MDSCs exploit multiple mechanisms to hamper anti-tumor immunity such as the expression of transforming growth factor-beta, reactive oxygen species, prostaglandin E2 (PGE2), IL-10, arginase-1, and indoleamine dioxygenase (16–22). This evidence concerns the gene IL10 and neoplasm.